Application of adenosine diphosphate

Abstract

This invention relates to the field of biological agents, and more particularly to the application of adenosine diphosphate; it provides the application of adenosine diphosphate in the preparation of drugs for treating bone defects; it provides a preparation for treating bone defects, comprising: adenosine diphosphate; the preparation of this invention does not require the collection of the patient's own bone marrow and peripheral blood, and will not cause additional damage or pain to the patient; the preparation containing adenosine diphosphate can accelerate bone tissue healing more conveniently and safely, providing conditions for early weight-bearing and functional exercises after surgery, and improving the patient's quality of life; the preparation method of the preparation of this invention is simple and easy to operate.

Description

Technical Field

[0001] This invention relates to the field of biological agents, and more particularly to the application of adenosine diphosphate. Background Technology

[0002] Extensive bone defects are a common condition in orthopedics, with common causes including trauma, bone infection, bone tumor resection, and congenital skeletal malformations. Due to the long treatment period and significant damage to the body, bone defects remain one of the major challenges in clinical practice.

[0003] The treatment of bone defects remains controversial in clinical practice. Surgical treatment is the most effective method for treating bone defects, such as bone grafting, the Masquelet technique, and the Ilizarov technique. However, the high complication rate and reoperation rate after surgery hinder the rehabilitation of limb function. Currently, there are reports of using bone marrow aspirate concentrate, platelet-rich plasma (PRP), and BMP protein as adjunctive therapies for bone defects. However, these methods require collecting the patient's own bone marrow and peripheral blood, which increases the patient's pain and trauma. In addition, numerous experimental studies have shown that the use of tissue engineering techniques to prepare composite scaffolds for repairing bone defects has achieved some success. However, due to the complexity of the preparation process, large variability, and low conversion rate, its clinical application still faces some obstacles.

[0004] Adenosine diphosphate (ADP) is composed of a pyrophosphate group, a pentose ribose, and the nucleobase adenine. It is a product of ATP dephosphorylation by ATPase. ADP participates in a variety of cellular processes, including respiration, biosynthetic reactions, movement, and cell division. However, there are currently no reports of ADP participating in the treatment of bone defects. Summary of the Invention

[0005] The purpose of this invention is to address the shortcomings of existing technologies by providing an application of adenosine diphosphate.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0007] The first aspect of the present invention is to provide the use of adenosine diphosphate in the preparation of a medicament for treating bone defects.

[0008] A second aspect of the present invention is to provide an formulation for treating bone defects, comprising: adenosine diphosphate.

[0009] Preferably, it also includes a pharmaceutically acceptable carrier.

[0010] More preferably, the pharmaceutically acceptable carrier is a 0.9% sodium chloride aqueous solution.

[0011] Preferably, in the formulation, the mass concentration of adenosine diphosphate is 0.01 mg / mL to 0.1 mg / mL.

[0012] A third aspect of the present invention is to provide a method for preparing the above-mentioned formulation, comprising the steps of:

[0013] Weigh the adenosine diphosphate, dissolve and mix it in the pharmaceutically acceptable carrier, and then filter it to obtain the formulation.

[0014] Preferably, in the filtration process, the filter element has a pore size of 0.2μm-0.3μm.

[0015] Preferably, the temperature for dissolving and mixing is 20℃-25℃.

[0016] The present invention adopts the above technical solution and has the following technical effects compared with the prior art:

[0017] The formulation of the present invention does not require the collection of the patient's own bone marrow and peripheral blood, and will not cause additional damage or pain to the patient. The formulation containing adenosine diphosphate can accelerate bone tissue healing more conveniently and safely, provide conditions for patients to bear weight and perform functional exercises in the early postoperative period, and improve the patient's quality of life. The preparation method of the formulation of the present invention is simple and easy to operate. Attached Figure Description

[0018] Figure 1 shows the Micro-CT results of a mouse skull defect model; where... Figure 1A This is a graph showing the results for the control group. Figure 1B The results for the experimental group are shown in the figure. Figure 1C Results of bone mineral density comparison; Figure 1D Results of the comparison of bone volume fraction; Figure 1E This is the ratio of bone surface area to tissue volume. Detailed Implementation

[0019] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0020] It should be noted that, unless otherwise specified, the embodiments and features described in the present invention can be combined with each other.

[0021] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but this is not intended to limit the scope of the invention.

[0022] Example

[0023] This embodiment provides a method for preparing an agent for treating bone defects, the steps of which include:

[0024] Weigh 1 mg of ADP powder and dissolve it in 10 mL of physiological saline. Filter the solution using a 0.22 μm filter to obtain the preparation with a mass concentration of 0.09 mg / mL.

[0025] Detection Examples

[0026] A skull defect model was established in four 8-week-old mice: the mice were routinely anesthetized and prepared. A 2cm incision was made along the midline of the skull, and the soft tissue was separated to expose the skull. A 2mm diameter full-thickness bone defect was created on the left and right sides of the mouse skull using a 2mm trephine. The wound was then closed.

[0027] The left skull defect of each mouse served as the control group, receiving 100 μL of physiological saline weekly, while the right skull defect served as the experimental group, receiving 100 μL of 0.85 μg / mL ADP weekly. After 8 weeks, each mouse was euthanized, and skull tissue was harvested and analyzed by MicroCT scanning. The results are shown in Figure 1. The BV / TV, BS / TV, and BMD of the skull defect in the experimental group were significantly higher than those in the control group, indicating that the bone defect in the experimental group mice had a higher content of new bone and that ADP promoted bone tissue healing.

[0028] In summary, the formulation of the present invention does not require the collection of the patient's own bone marrow and peripheral blood, and will not cause additional damage or pain to the patient. The formulation containing adenosine diphosphate can accelerate bone tissue healing more conveniently and safely, provide conditions for patients to bear weight and perform functional exercises in the early postoperative period, and improve the patient's quality of life. The preparation method of the formulation of the present invention is simple and easy to operate.

[0029] The above description is merely a preferred embodiment of the present invention and does not limit the implementation and protection scope of the present invention. Those skilled in the art should realize that any equivalent substitutions and obvious changes made based on the description and illustrations of the present invention should be included within the protection scope of the present invention.

Claims

1. Application of adenosine diphosphate in the preparation of drugs for treating bone defects.

2. The application according to claim 1, characterized in that, The drug also includes: a pharmaceutically acceptable carrier.

3. The application according to claim 2, characterized in that, The pharmaceutically acceptable carrier is a 0.9% sodium chloride aqueous solution.

4. The application according to claim 2, characterized in that, In the drug, the mass concentration of adenosine diphosphate is 0.01 mg / mL to 0.1 mg / mL.

5. The application according to any one of claims 2-4, characterized in that, The preparation steps of the drug include: Weigh the adenosine diphosphate, dissolve and mix it in the pharmaceutically acceptable carrier, and then filter it to obtain the drug.

6. The application according to claim 5, characterized in that, In the filtration process, the filter element used has a pore size of 0.2μm-0.3μm.

7. The application according to claim 5, characterized in that, The temperature for dissolving and mixing is 20℃-25℃.

Images